Alexion Pharmaceuticals Price Target Increased to $123.00 by Analysts at Cowen and Company (ALXN)
Investment analysts at Cowen and Company increased their price target on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $115.00 to $123.00 in a note issued to investors on Friday, AR Network reports. The firm currently has an “outperform” rating on the stock. Cowen and Company’s price target points to a potential downside of 1.73% from the company’s current price.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 7.26% during mid-day trading on Friday, hitting $125.17. The stock had a trading volume of 2,626,550 shares. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $125.65. The stock’s 50-day moving average is $111.0 and its 200-day moving average is $100.2. The company has a market cap of $24.478 billion and a price-to-earnings ratio of 66.53.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 24th. The company reported $0.83 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter last year, the company posted $0.60 earnings per share. Alexion Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of Alexion Pharmaceuticals from $132.00 to $138.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Barclays raised their price target on shares of Alexion Pharmaceuticals from $121.00 to $127.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Alexion Pharmaceuticals from $131.00 to $138.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $121.72.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.